

Technology Advisory Committee C Interests Register

Faricimab for treating wet age-related macular degeneration [ID3898]

Publication Date: 29/06/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	Committee member	Direct - financial	<p>In 2020 Mr Chambers helped co-ordinate a training programme run by the University of Utrecht in Real World Evidence for Roche, but this did not involve any specific consideration of Roche products.</p> <p>In 2021-22, Mr Chambers participated in an advisory panel for Pfizer, manufacturer of a possible comparator therapy, but in an unrelated disease area (prostate cancer).</p>	N/A	25.05.2022	N/A	It was agreed his declaration would not prevent Mr Chambers from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee member	Direct - financial	Dr Nicholas has attended paid advisory boards with Roche, and with Novartis, manufacturer of a possible comparator therapy, but in an unrelated area (multiple sclerosis).	N/A	26.05.2022	N/A	It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Claire Bailey	Clinical expert	Direct – financial	<p>Dr Bailey has attended advisory board meetings for Novartis, Bayer, Alimera Sciences, Boehringer-Ingelheim and Roche. She has received lecture fees from Novartis, Bayer and Alimera Sciences and is involved with clinical trial advisory work for Janssen.</p> <p>Dr Bailey has also received travel support to attend conferences from Bayer, Novartis, Alimera Sciences.</p> <p>Her employer Bristol Eye Hospital has received research funds for clinical trial recruitment/participation from Novartis, Bayer, Boehringer Ingelheim and Roche.</p>	N/A	11.10.2021	N/A	It was agreed that his declaration would not prevent Dr Bailey from providing expert advice to the committee.
Professor Ian Pearce	Clinical expert	Direct financial and non-financial and indirect non-financial	<p>Professor Pearce has received consultancy and lecture fees and travel support from Roche, Novartis, Bayer and Allergan.</p> <p>He is the principal investigator of RHINE and RHONE-X studies of</p>	N/A	11.10.2021	N/A	It was agreed that his declaration would not prevent Professor Pearce from providing expert advice to the committee.

			faricimab and is co-author of pivotal trial publications relevant to faricimab.				
Stephen Scowcroft	Patient expert	Direct – financial	Mr Scowcroft’s employer, the Macular Society, receives financial support from a number of pharma companies. None of the companies have direct editorial input into Macular Society information or activities.	N/A	12.10.2021	N/A	It was agreed that his declaration would not prevent Mr Scowcroft from providing expert advice to the committee.